107 results
Page 2 of 6
S-4
1qwui1
10 May 23
Registration of securities issued in business combination transactions
9:56pm
425
EX-2.1
2adklqbe4g2rok glnsc
30 Mar 23
Business combination disclosure
8:51am
8-K
EX-2.1
ok030ai
30 Mar 23
Form of Parent Stockholder Support Agreement
8:50am
DEFA14A
l4aewe
16 Dec 22
Additional proxy soliciting materials
5:16pm
8-K
EX-99.1
q7ghun
16 Dec 22
Diffusion Pharmaceuticals Announces Agreement with LifeSci Special Opportunities
5:10pm
PRRN14A
0nzt3bqx8vyv29fogad
6 Dec 22
Revised preliminary proxy statement filed by non-management
8:30am
DEFA14A
EX-99.1
plc7hs
5 Dec 22
Additional proxy soliciting materials
9:59pm
8-K
EX-99.1
cf44 psnbl
5 Dec 22
Diffusion has a highly engaged and independent board that possesses the right skills and experience to execute the strategic review process
9:58pm
PRRN14A
t8b99cx27cl2f zy
2 Dec 22
Revised preliminary proxy statement filed by non-management
2:36pm
PREC14A
10p9fsdjt4vibuc
23 Nov 22
Preliminary proxy with contested solicitation
11:26am
8-K
EX-99.1
f0p73j3rx5d
18 Nov 22
Diffusion Pharmaceuticals Sees Significant Progress in its Strategic Review Process
4:40pm
DEFA14A
EX-99.1
6591zzp16skt4mm4u qj
14 Nov 22
Additional proxy soliciting materials
7:41am
8-K
EX-99.1
ipx8t iy6lq9dgx9qi
14 Nov 22
Diffusion Pharmaceuticals Sees Significant Progress in its Strategic Review Process
7:40am
8-K
EX-99.1
k1ii6ozs17s6gyy4o492
27 Oct 22
Diffusion Pharmaceuticals Announces Strategic Review Process to Evaluate Value-Enhancing Alternatives including Opportunities to Better Leverage TSC
4:15pm
8-K
EX-99.1
6gb 00iqi85
16 Aug 22
Diffusion Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update
4:21pm
8-K
EX-99.1
fv1je4kvaxdf7 9au9k
27 Jul 22
Other Events
7:30am
424B5
fyrpgf7csv 0y09d
22 Jul 22
Prospectus supplement for primary offering
4:15pm